Compare Sun Pharma with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs CADILA HEALTHCARE - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA CADILA HEALTHCARE SUN PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 84.7 33.9 249.6% View Chart
P/BV x 3.6 6.0 60.7% View Chart
Dividend Yield % 0.6 0.6 101.4%  

Financials

 SUN PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    SUN PHARMA
Mar-20
CADILA HEALTHCARE
Mar-20
SUN PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs484352 137.4%   
Low Rs315207 152.6%   
Sales per share (Unadj.) Rs136.9139.2 98.3%  
Earnings per share (Unadj.) Rs17.511.8 148.3%  
Cash flow per share (Unadj.) Rs26.018.6 140.1%  
Dividends per share (Unadj.) Rs4.003.50 114.3%  
Dividend yield (eoy) %1.01.3 79.9%  
Book value per share (Unadj.) Rs188.7101.4 186.1%  
Shares outstanding (eoy) m2,399.261,023.74 234.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.92.0 145.5%   
Avg P/E ratio x22.923.7 96.4%  
P/CF ratio (eoy) x15.415.0 102.1%  
Price / Book Value ratio x2.12.8 76.8%  
Dividend payout %22.929.8 77.0%   
Avg Mkt Cap Rs m958,864286,033 335.2%   
No. of employees `00017.813.4 132.5%   
Total wages/salary Rs m63,62424,145 263.5%   
Avg. sales/employee Rs Th18,490.610,632.7 173.9%   
Avg. wages/employee Rs Th3,582.61,801.2 198.9%   
Avg. net profit/employee Rs Th2,357.6898.5 262.4%   
INCOME DATA
Net Sales Rs m328,375142,531 230.4%  
Other income Rs m6,3601,139 558.4%   
Total revenues Rs m334,735143,670 233.0%   
Gross profit Rs m69,89824,198 288.9%  
Depreciation Rs m20,5286,965 294.7%   
Interest Rs m3,0273,418 88.6%   
Profit before tax Rs m52,70214,954 352.4%   
Minority Interest Rs m0288 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-2,6060-   
Tax Rs m8,2283,198 257.3%   
Profit after tax Rs m41,86812,044 347.6%  
Gross profit margin %21.317.0 125.4%  
Effective tax rate %15.621.4 73.0%   
Net profit margin %12.88.5 150.9%  
BALANCE SHEET DATA
Current assets Rs m316,54287,154 363.2%   
Current liabilities Rs m157,06482,694 189.9%   
Net working cap to sales %48.63.1 1,552.0%  
Current ratio x2.01.1 191.2%  
Inventory Days Days8871 122.6%  
Debtors Days Days10594 111.6%  
Net fixed assets Rs m243,102133,236 182.5%   
Share capital Rs m2,3991,024 234.3%   
"Free" reserves Rs m450,245102,733 438.3%   
Net worth Rs m452,645103,757 436.3%   
Long term debt Rs m20,28932,146 63.1%   
Total assets Rs m682,525236,866 288.1%  
Interest coverage x18.45.4 342.5%   
Debt to equity ratio x00.3 14.5%  
Sales to assets ratio x0.50.6 80.0%   
Return on assets %6.66.5 100.8%  
Return on equity %9.211.6 79.7%  
Return on capital %11.213.7 81.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m74,21952,752 140.7%   
Fx outflow Rs m27,96414,504 192.8%   
Net fx Rs m46,25538,248 120.9%   
CASH FLOW
From Operations Rs m65,54825,054 261.6%  
From Investments Rs m-25,888-10,123 255.7%  
From Financial Activity Rs m-57,151-10,942 522.3%  
Net Cashflow Rs m-13,8573,989 -347.4%  

Share Holding

Indian Promoters % 63.7 74.8 85.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 8.3 61.8%  
FIIs % 23.0 5.9 389.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 11.0 75.5%  
Shareholders   133,026 44,069 301.9%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  WOCKHARDT  AUROBINDO PHARMA  

Compare SUN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


May 7, 2021 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - DR. DATSONS LABS COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS